Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer
- PMID: 37655984
- DOI: 10.1002/ijc.34708
Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer
Abstract
Prostate cancer (PCa) is a highly heterogeneous disease in terms of its molecular makeup and clinical prognosis. The prostate tumor microenvironment (TME) is hypothesized to play an important role in driving disease aggressiveness, but precise mechanisms remain elusive. In our study, we used spatial transcriptomics to explore for the first time the spatial gene expression heterogeneity within primary prostate tumors from patients with metastatic disease. In total, we analyzed 5459 tissue spots from three PCa patients comprising castration-resistant (CRPC) and neuroendocrine (NEPC) disease stages. Within CRPC, we identified a T cell cluster whose activity might be impaired by nearby regulatory T cells, potentially mediating the aggressive disease phenotype. Moreover, we identified Hallmark signatures of epithelial-mesenchymal transition in a cancer-associated fibroblast (CAF) cluster, indicating the aggressive characteristic of the primary TME leading to metastatic dissemination. Within NEPC, we identified active immune-stroma cross-talk exemplified by significant ligand-receptor interactions between CAFs and M2 macrophages. Further, we identified a malignant cell population that was associated with the down-regulation of an immune-related gene signature. Lower expression of this signature was associated with higher levels of genomic instability in advanced PCa patients (SU2C cohort, n = 99) and poor recurrence free survival in early-stage PCa patients (TCGA cohort, n = 395), suggesting prognostic biomarker potential. Taken together, our study reveals the importance of whole transcriptome profiling at spatial resolution for biomarker discovery and for advancing our understanding of tumor biology.
Keywords: cancer-associated fibroblasts; immune checkpoint targets; metastatic prostate cancer; spatial gene expression; tumor microenvironment.
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Similar articles
-
Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response.BMC Cancer. 2025 Apr 30;25(1):813. doi: 10.1186/s12885-025-14212-x. BMC Cancer. 2025. PMID: 40307786 Free PMC article.
-
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34646089 Free PMC article.
-
Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.Medicine (Baltimore). 2023 Aug 11;102(32):e34611. doi: 10.1097/MD.0000000000034611. Medicine (Baltimore). 2023. PMID: 37565899 Free PMC article.
-
Novel Therapeutic Targets and Biomarkers Associated with Prostate Cancer-Associated Fibroblasts (CAFs).Crit Rev Oncog. 2022;27(1):1-24. doi: 10.1615/CritRevOncog.2022043478. Crit Rev Oncog. 2022. PMID: 35993976 Review.
-
Novel signatures of prostate cancer progression and therapeutic resistance.Expert Opin Ther Targets. 2023 Jul-Dec;27(12):1195-1206. doi: 10.1080/14728222.2023.2293757. Epub 2023 Dec 30. Expert Opin Ther Targets. 2023. PMID: 38108262 Review.
Cited by
-
Applications and prospects of spatial transcriptomics in prostate cancer research: A narrative review.Curr Urol. 2025 Sep;19(5):303-308. doi: 10.1097/CU9.0000000000000288. Epub 2025 May 23. Curr Urol. 2025. PMID: 40894285 Free PMC article.
-
Application and new findings of scRNA-seq and ST-seq in prostate cancer.Cell Regen. 2024 Oct 29;13(1):23. doi: 10.1186/s13619-024-00206-w. Cell Regen. 2024. PMID: 39470950 Free PMC article. Review.
-
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.Prostate. 2024 May;84(7):623-635. doi: 10.1002/pros.24682. Epub 2024 Mar 7. Prostate. 2024. PMID: 38450798 Free PMC article. Review.
-
Cancer therapy resistance from a spatial-omics perspective.Clin Transl Med. 2025 Jul;15(7):e70396. doi: 10.1002/ctm2.70396. Clin Transl Med. 2025. PMID: 40677104 Free PMC article. Review.
-
Silencing SPP1 in M2 macrophages inhibits the progression of castration-resistant prostate cancer via the MMP9/TGFβ1 axis.Transl Androl Urol. 2024 Jul 31;13(7):1239-1255. doi: 10.21037/tau-24-127. Epub 2024 Jul 12. Transl Androl Urol. 2024. PMID: 39100821 Free PMC article.
References
REFERENCES
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
-
- Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88(3-4):166-173. doi:10.1093/jnci/88.3-4.166
-
- Farach A, Ding Y, Lee M, et al. Neuronal trans-differentiation in prostate cancer cells. Prostate. 2016;76(14):1312-1325. doi:10.1002/pros.23221
-
- Andersen LB, Norgaard M, Rasmussen M, et al. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors. J Pathol. 2021;255:155-165. doi:10.1002/path.5757
-
- R core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria; 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical